Human immunodeficiency virus (HIV)-positive patients are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; patients must also have a CD4 count > 350 cells/mm^3 with an undetectable viral load

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV patients treated with regimens that have low cytochrome P450 (CYP450) inhibition may be allowed as long as the patient’s general health and cluster of differentiation (CD)4 counts are within acceptable levels

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are INELIGIBLE

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Patients on antiretroviral therapy.

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is not required for inclusion in this study

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible due to potential drug-drug interactions with PT2385

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive participants; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Patients should be excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Participants known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated; screening for HIV infection at baseline is not required

Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible

Medical history:\r\n* History of intracranial abscess within 6 months prior to start of study therapy\r\n* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS)\r\n* NOTE: HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with nivolumab\r\n* Appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibody;

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Known history of human immunodeficiency virus (HIV); testing is not required in the absence of prior documentation or known history; HIV-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; it is not necessary to conduct HIV testing at screening; patients who are HIV-positive with undetectable viral loads, not on interacting antiretroviral therapy, and have CD4 counts above 300/mm^3 may be eligible after discussion with the principal investigator

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy

Known human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy

Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with prexasertib and LY3300054. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy such as prexasertib.

Known HIV-positive patients on combination antiretroviral therapy.

The participant is known to be positive for the human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), or hepatitis C virus (HCV) ribonucleic acid (RNA). HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with atezolizumab

The participant is known to be positive for the human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), or hepatitis C (HCV) ribonucleic acid (RNA); HIV-positive participants on combination antiretroviral therapy are ineligible

ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Participants with a known history of human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive individuals on combination anti-retroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

The participant is known to be positive for the human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), or hepatitis C virus (HCV) ribonucleic acid (RNA); HIV-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with pembrolizumab

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

A known history of human immunodeficiency virus (HIV) seropositivity; HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive participants; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Patients may not have known human immunodeficiency virus (HIV) infection; HIV-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive participants are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Patients with human immunodeficiency virus (HIV) who are unable or unwilling to stop antiretroviral therapy for the duration of therapy may not be enrolled

Known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded

Patients with active human immunodeficiency virus (HIV) or hepatitis C; (HIV-positive patients on combination antiretroviral therapy or hepatitis C-positive patients on antiviral therapy are ineligible)

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients who are not on highly active anti-retroviral therapy (HAART) and have CD4 counts > 500 will be considered on an individual basis

Patients with known prior human immunodeficiency virus (HIV)-positive status on combination antiretroviral therapy are ineligible; known prior HIV-positive patients with cluster of differentiation (CD)4+ =< 500/mm^3 are ineligible (HIV testing is not required as part of this study)

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV) positive patients on antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patient known to be human immunodeficiency virus (HIV)-positive and requiring antiretroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with chemotherapeutic drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy.

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions vemurafenib and cobimetinib

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with study drug. In addition, these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

COHORT 2: TRIPLE NEGATIVE BREAST CANCER: HIV-positive patients on combination antiretroviral therapy are ineligible

COHORT 3: ENDOMETRIAL CANCER: HIV-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy

Individuals who are known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible

Patients with human immunodeficiency virus (HIV) on antiretroviral therapy are ineligible

The participant is known to be positive for the human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), or hepatitis c virus (HCV) ribonucleic acid (RNA); HIV-positive participants on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with apalutamide and abiraterone. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with the study drugs. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with meclizine.

Human deficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV) seropositive patients with acceptable organ function who meet the patient selection criteria, and who are not on combination antiretroviral therapy, and whose absolute CD4+ count is >= 400 cells per cubic millimeter of blood, will be eligible; however, HIV positive patients on combination antiretroviral therapy will be ineligible, because of the potential for pharmacokinetic interactions with cabozantinib

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Patients who are known human immunodeficiency virus (HIV), hepatitis B or hepatitis C positive; HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; HIV, hepatitis B and hepatitis C testing is not required for patients not known to have those infections

Participants known to be human immunodeficiency virus (HIV)-positive and on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Patients are excluded if they have known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy

Patients with known human immunodeficiency virus (HIV) on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV) positive patients with CD4 counts below 500 OR who are not on a stable dose of antiretroviral therapy (for at least 1 month prior to registration) are ineligible

Known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed)\r\n* HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive patients who are on combination antiretroviral therapy; (this is because of the potential for pharmacokinetic interactions with denosumab)

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible provided they have stable CD4 counts above 250

Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible; HIV testing is not required, but patients must not be known to be HIV-positive

Patients who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy

Human immunodeficiency virus (HIV) infection: HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known history of human immunodeficiency virus (HIV) infection (testing not mandatory); NOTE: HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ribociclib; in addition, these subjects are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients with uncontrolled HIV despite combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients on combination antiretroviral therapy for the treatment of human immunodeficiency virus (HIV) are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV) infection\r\n* HIV-positive patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with oral THU-Dec; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Subjects who are human immunodeficiency virus (HIV)-positive will be excluded from the study\r\n* Appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; also include whether HIV testing is required for this study, or only if a known diagnosis will be excluded

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

PHASE I AND II SCLC AND UROTHELIAL CARCINOMA EXPANSION COHORT: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

mCRPC EXPANSION COHORT: HIV-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Know human immunodeficiency virus (HIV) positivity on combination antiretroviral therapy

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy

Human immunodeficiency virus (HIV) positive (+) with a cluster of differentiation (CD)4 count < 200 are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS); HIV-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Patients who are known to be human immunodeficiency positive (HIV)-positive and are on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vandetanib/metformin

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Immunocompromised patients or patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients with a known human immunodeficiency virus (HIV)-positive test on combination antiretroviral therapy are ineligible for the initial first-in-man trial

The subject is known to be positive for the human immunodeficiency virus (HIV) and is receiving antiretroviral therapies; subjects known to be HIV-positive who do not require antiretroviral therapy will be eligible if they meet other entry criteria

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients known to be human immunodeficiency virus (HIV)-positive patients and on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral treatment are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded

History of human immunodeficiency virus (HIV) or HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-infected patients should be receiving or willing to initiate an effective combination antiretroviral therapy (cART) regimen

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

HIV positive individuals on combination antiretroviral therapy are ineligible

Patients receiving antiretroviral therapy (highly active antiretroviral therapy [HAART]) for human immunodeficiency virus (HIV) infection are excluded from the study

Patients known to be human immunodeficiency virus (HIV) positive must be stable and currently receiving antiretroviral therapy with a CD4 count > 400

Human immunodeficiency (HIV)-positive individuals on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with STA-9090; in addition, these individuals are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

HIV-positive patients on combination antiretroviral therapy are ineligible because of unknown potential for interactions with cenersen.

Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with copanlisib or nivolumab\r\n* Patients with human immunodeficiency virus (HIV): HIV-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated; patients with evidence of hepatitis B virus (HBV) are eligible provided there is minimal hepatic injury and the patient has undetectable HBV on suppressive HBV therapy; patient must be willing to maintain adherence to HBV therapy\r\n* Patients with previously treated and eradicated hepatitis C virus (HCV) who have minimal hepatic injury are eligible

Human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with lenvatinib

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on highly active antiretroviral therapy (HAART) are excluded

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with AMG 232; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy

Participants known to be human immunodeficiency virus (HIV)-positive are excluded (Note: HIV testing is not required prior to enrollment). HIV-positive individuals on combination antiretroviral therapy are ineligible

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; known HIV-positive individuals who are not on combination antiretroviral therapy are not eligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

TUMOR BIOPSY SEQUENCING: Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

TREATMENT: HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; however, HIV-positive patients without an acquired immune deficiency syndrome (AIDS)-defining diagnosis who are not receiving agents with the potential for pharmacokinetic (PK) interactions with ABT-888 may be eligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Immunocompromised patients, e.g., patients who are known to be serologically positive for human immunodeficiency virus (HIV); HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients not on antiviral therapy with undetectable viral loads and CD4 counts > 300, and after confirmation of eligibility after discussing with the study chair are eligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient’s cluster of differentiation (CD)4+ count is below the institutional lower limit of normal

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients who are positive for human immunodeficiency virus type 1 (HIV-1) and are receiving combination anti-retroviral therapy

Human immunodeficiency (HIV)-positive participants on combination antiretroviral therapy are ineligible

Participants known to be human immunodeficiency virus (HIV)-positive are excluded (note: HIV testing is not required prior to enrollment); HIV-positive individuals on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Has a known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies); HIV-positive participants on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder; HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; if an HIV-positive patient has adequate cluster of differentiation (CD4) counts (CD4 above the lower limit of institutional normal) and is on antiretroviral therapy with newer agents, which are not strong cytochrome (CYP) inhibitors, they will be eligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV) or other history of immunodeficiency disorder \r\n* NOTE: HIV-positive patients taking combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are not eligible

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Human immunodeficiency virus (HIV) positive patients who are on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

PHASE II: HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with veliparib; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Negative human immunodeficiency virus (HIV) blood test within 21 days of study entry; HIV-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients with well-controlled disease, as determined by CD4 count and viral load, who are on antiretroviral therapy that does not contain a strong inducer or inhibitor of CYP3A4 are allowed on trial; HIV-positive patients on combination antiretroviral therapy with strong inducers or inhibitors of CYP3A4 are ineligible; patients with poorly controlled HIV are not eligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Participant is known to be positive for the human immunodeficiency virus (HIV), hepatitis B surface antigen (HepBsAg), or hepatitis C virus (HCV) RNA; HIV-positive participants are ineligible because of the potential for pharmacokinetic interactions of combination antiretroviral therapy with study drugs; in addition, these participants are at increased risk of fatal infections when treated with marrow-suppressive therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV positive patients on antiretroviral therapy regimen must be willing to suspend all highly active antiretroviral therapy (HAART) except in circumstances described

Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible; unless the patient’s CD4 count is below the institutional lower limit of normal

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV testing is required only for patients deemed to be high-risk

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated

Patients who are known to have human immunodeficiency virus (HIV) or are on combination antiretroviral therapy are ineligible

Subjects known to be human immunodeficiency virus (HIV)-positive, including those on combination antiretroviral therapy, are ineligible

Patients who are human immunodeficiency virus (HIV) positive must be willing to comply with effective antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy which include cytochrome p450 inhibitors are ineligible; patients with CD4 counts less than 300 CD4+ cells/mm^3 and or a high viral load are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated; HIV testing prior to enrollment is not required for screening but strongly encouraged for patients with no documented prior HIV assessment

HIV-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive participants on CYP3A4 modulating antiretroviral therapy are ineligible

Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

HIV-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV and HIV testing is not otherwise required

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients with inadequate cluster of differentiation (CD)4 counts or those who are on combination antiretroviral therapy with strong cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) effects are ineligible for this trial

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Confirmed human immunodeficiency virus (HIV) positive whether or not on antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

PHASE II: Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible

Patients on combination antiretroviral therapy, i.e. those who are human immunodeficiency virus (HIV)-positive, are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; Note: patients not on antiretroviral therapies are eligible for this study

Because patients with immune deficiency are at increased risk of lethal infections when treated with bone marrow suppressive therapy, human immunodeficiency virus (HIV)-positive patients are excluded from the study; for patients receiving combination antiretroviral therapy, the potential impact of pharmacokinetic interactions with HCQ and VEM is unknown; appropriate studies may be undertaken in patients with HIV and those receiving combination anti-retroviral therapy in the future

HIV-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible so long as they meet all other criteria; HIV-positive individuals who are not on combination antiretroviral therapy are not eligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients or those on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with mFOLFIRINOX. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Patients must not have human immunodeficiency virus (HIV) or be taking highly active antiretroviral therapy (HAART) therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy will be eligible unless the cluster of differentiation (CD)4 count is < 200 cells/mm^3 within one month of study enrollment

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are eligible for enrollment and will be monitored closely for potential pharmacokinetic interactions with neratinib

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive individuals on combination antiretroviral therapy are ineligible

EXPANSION COHORT ONLY: HIV-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with bevacizumab. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated.

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with vorinostat; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy

Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV-positive patients with cluster of differentiation (CD)4+ =< 500/mm^3 are ineligible; appropriate studies will be undertaken in this group of patients when indicated

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; HIV- positive patients who are not on combination antiretroviral therapy (cART) and have CD4 counts > 500 are eligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known HIV-positive individuals on combination antiretroviral therapy.

Patients with human immunodeficiency virus (HIV) whom are not receiving antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patient’s cluster of differentiation (CD)4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients receiving combination antiretroviral therapy are ineligible; HIV testing is not required for study enrollment and optional

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with tretinoin; in addition, these patients are at increased risk of lethal infections when treated with marrow suppressive therapy; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy; NOTE: HIV-positive patients on combination antiretroviral therapy are ineligible; in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy

Patients that are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy

Patient is human immunodeficiency virus (HIV)-positive and is receiving combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy known to interact with CYP isoenzymes are ineligible; in addition, HIV patients with CD4 count < 200 cells/uL are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

HIV-positive patients on combination antiretroviral therapy.

Human immunodeficiency virus-positive patients receiving combination anti-retroviral therapy are excluded from the study

HIV-positive patients on combination antiretroviral therapy are ineligible

Subjects who are human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)-related illness (HIV-positive subjects on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in subjects receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible if they have been on antiretrovirals (ARVs) for >= 6 months and undetectable viral loads

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; HIV-positive individuals on highly active antiretroviral therapy (HAART) will be considered eligible if they have demonstrated good compliance and have a cluster of differentiation (CD)4 count > 500

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are eligible, unless the patient’s CD4 count is below the institutional lower limit of normal, or the patient is taking prohibited CYP3A4/5 strong inhibitors or inducers

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy are ineligible

Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with erlotinib; in addition, these patients are at increased risk of lethal infections; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human Immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy are excluded from this study; HIV positive patients not receiving antiretroviral therapy are excluded

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients on antiretroviral therapy are excluded from the study

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV) positive patients on combination antiretroviral therapy are ineligible

Known human immunodeficiency virus (HIV)-positivity on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible; this applies only to patients who have a documented history of HIV; HIV testing is not otherwise required

Participants known to be positive for the human immunodeficiency virus (HIV), hepatitis B antigen (HepBsAg), or hepatitis C virus (HCV) ribonucleic acid (RNA); HIV-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible; appropriate studies will be undertaken in participants receiving combination antiretroviral therapy when indicated

Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapies

Known human immunodeficiency virus (HIV)-positivity and on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

HIV-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Patients with known human immunodeficiency virus (HIV) are ineligible; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with ferumoxytol

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Patient must not be known to be human immunodeficiency virus (HIV)-positive on combination antiretroviral therapy

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive individuals on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive participants on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible

Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with zolpidem; appropriate studies will be undertaken in patients receiving combination antiretroviral therapy when indicated

Known human immunodeficiency virus (HIV)-positive patients on combination anti-retroviral therapy are ineligible; appropriate studies will be undertaken in patients receiving combination anti-retroviral therapy when indicated

Human immunodeficiency virus (HIV)-positive patients receiving combination anti-retroviral therapy are excluded from the study

HIV-positive individuals on combination antiretroviral therapy.

HIV-positive individuals on combination antiretroviral therapy.

HIV-positive individuals on combination antiretroviral therapy.

Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are ineligible